MOG and demyelinating disease: By targeting N-glycan branching in immune cells, GlcNAc may also be relevant to other inflammatory and demyelinating disorders, including neuromyelitis optica and myelin oligodendrocyte glycoprotein antibody disease, as well as non-neurological T cell and or B cell dependent autoimmune diseases.